JSPR - Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress | Benzinga
REDWOOD CITY, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today is presenting preclinical data demonstrating the effect of briquilimab on hematopoietic stem cells (HSCs) at the European Hematology Association (EHA) Hybrid Congress, being held June 13 – 16, 2024 in Madrid, Spain.
The study being presented evaluated the molecular basis of inhibition of the stem cell factor (SCF)/c-Kit signaling pathway via briquilimab and its functional impact on healthy human HSC survival, proliferation, and differentiation. Results from the study demonstrate that blocking of SCF/c-Kit signaling by briquilimab does not cause apoptosis of HSCs, and that HSCs cultured in the presence of briquilimab differentiate directly into CD34- cells with higher c-Kit expression and without increased CD38 expression.
"We are pleased to present preclinical data demonstrating the effect of c-Kit inhibition on the HSC compartment," said Wendy Pang, M.D., Ph.D., Senior Vice President, Research and Translational Medicine of Jasper. "While blocking of SCF/c-Kit signaling by briquilimab does lead to mast cell apoptosis, it is important that it does not have a similar effect on healthy HSCs, and these data indicate that briquilimab instead skews them towards a distinct alternative HSC differentiation pathway. We believe the results of the study align with those observed to-date in clinical trials of anti-c-Kit agents and support the safety profile of briquilimab in mast cell diseases."
Details of the presentation are below:
Title: Briquilimab Potently Inhibits SCF/c-Kit Signaling, Which Does Not Induce Healthy HSC Apoptosis, But Skews HSC Differentiation Potential
Abstract Number: P1391
Session Type: Poster Session
Session Title: Hematopoiesis, Stem Cells and Microenvironment
Location: Poster Area (Hall 7)
Date/Time: Friday, June 14, 2024; 6:00-7:00pm CEST
The presentation will be available on the EHA website as well as the events page on the Jasper Therapeutics IR website.
About Briquilimab
Briquilimab (formerly JSP191) is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, ...